Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

Xavier Leleu, Anne Sophie Moreau, Edie Weller, Aldo M. Roccaro, Vale Rie Coiteux, Robert Manning, Marybeth Nelson, Renee Leduc, Daniela Robu, Sophie Dupire, Evdoxia Hatjiharissi, Nicholas Burwick, Stephane Darre, Bernadette Hennache, Steven P. Treon, Thierry Facon, Morie A. Gertz, Irene M. Ghobrial

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


The serum IgM level has been utilised as a marker of tumor progression and to assess response to therapy in patients with Waldenstrom macroglobulinemia (WM). However, there are many limitations to the IgM protein level. The objective of this study was to evaluate the association of known tumor burden markers and prognostic factors with serum free light chain (sFLC) in 98 patients with WM. We demonstrated that sFLC measurement accurately differentiated IgM-MGUS compared with WM reflecting a measurement of tumor burden. In univariate and multivariate analysis, median sFLC at the cut-off at 60 mg/L was higher for WM patients with low hemoglobin and high β2M, when we applied the WM-IPSS cut-offs, but showed no association with IgM level. This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients.

Original languageEnglish (US)
Pages (from-to)1104-1107
Number of pages4
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 2008


  • Serum-free light chain
  • Tumor burden marker
  • Waldenstrom macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia'. Together they form a unique fingerprint.

Cite this